Search results for "renal insufficiency"

showing 5 items of 175 documents

Chronic kidney disease and dyslipidaemia

2016

Chronic kidney disease (CKD) has to be considered as a high, or even very high risk cardiovascular risk condition, since it leads to an increase in cardiovascular mortality that continues to increase as the disease progresses. An early diagnosis of CKD is required, together with an adequate identification of the risk factors, in order to slow down its progression to more severe states, prevent complications, and to delay, whenever possible, the need for renal replacement therapy. Dyslipidaemia is a factor of the progression of CKD that increases the risk in developing atherosclerosis and its complications. Its proper control contributes to reducing the elevated cardiovascular morbidity and …

medicine.medical_specialtymedicine.medical_treatmentRenal functionDisease030204 cardiovascular system & hematologyurologic and male genital diseases03 medical and health sciences0302 clinical medicineRisk FactorsmedicineHumans030212 general & internal medicineRenal replacement therapyRenal Insufficiency ChronicIntensive care medicineDyslipidemiasGeneral Environmental ScienceCardiovascular mortalitybusiness.industryAnticholesteremic AgentsGeneral EngineeringCholesterol LDLmedicine.diseaseRenal Replacement TherapyCardiovascular DiseasesRenal transplantDisease ProgressionPhysical therapyGeneral Earth and Planetary SciencesHydroxymethylglutaryl-CoA Reductase InhibitorsbusinessVery high riskDyslipidemiaKidney diseaseClínica e Investigación en Arteriosclerosis (English Edition)
researchProduct

Ultra-low contrast coronary angiography and zero-contrast percutaneous coronary intervention for prevention of contrast-induced nephropathy: step-by-…

2019

Contrast-induced nephropathy is a serious complication after intravascular administration of iodinated contrast media and is associated with numerous adverse outcomes. Its prevalence is particularly high in patients with multiple comorbidities who undergo coronary angiography and percutaneous coronary intervention (PCI). Currently, the only effective method to prevent contrast-induced kidney injury is adequate hydration and a reduction of contrast volume during the intervention. Recently, new approaches aiming to minimize contrast usage have been proposed, i.e., ultra-low contrast angiography and zero-contrast PCI. However, neither tutorials for these techniques nor reviews of their outcome…

medicine.medical_specialtyzero-contrast percutaneous coronary interventionmedia_common.quotation_subjectmedicine.medical_treatmentContrast-induced nephropathylcsh:Medicine030204 cardiovascular system & hematologyNephropathyrenal insufficiency03 medical and health sciences0302 clinical medicineIntervention (counseling)medicineContrast (vision)030212 general & internal medicineIntensive care medicinemedia_commonReview Paperbusiness.industrylcsh:RAcute kidney injuryPercutaneous coronary interventionmedicine.diseaseacute kidney injurycontrast-induced nephropathyConventional PCICardiology and Cardiovascular MedicinebusinessComplicationchronic kidney diseaseAdvances in Interventional Cardiology
researchProduct

Zero-contrast percutaneous coronary interventions to preserve kidney function in patients with severe renal impairment and hemodialysis subjects

2019

Introduction Zero-contrast percutaneous coronary intervention (zero-PCI) is a new method for prevention of contrast-induced acute kidney injury (AKI) in patients with chronic kidney disease (CKD). However, evidence for its feasibility, safety and clinical utility is limited to reports of single cases or series of patients. Aim To present outcomes of zero-PCI in patients with severe CKD, including hemodialysis subjects, who were treated with this procedure in order to preserve their renal function. Material and methods Twenty-nine zero-PCIs were performed, mostly as a staged procedure, in 20 patients with advanced CKD. In this group, 4 patients were treated with hemodialysis but presented pr…

medicine.medical_specialtyzero-contrast percutaneous coronary interventionmedicine.medical_treatmentContrast-induced nephropathylcsh:MedicineRenal function030204 cardiovascular system & hematologyRevascularizationurologic and male genital diseasesrenal insufficiency03 medical and health sciences0302 clinical medicine0502 economics and businessmedicineRenal replacement therapyOriginal Paperbusiness.industrylcsh:R05 social sciencesAcute kidney injuryPercutaneous coronary interventionmedicine.diseaseSurgeryacute kidney injurycontrast-induced nephropathy050211 marketingHemodialysisCardiology and Cardiovascular MedicinebusinessKidney diseasePostępy w Kardiologii Interwencyjnej = Advances in Interventional Cardiology
researchProduct

Significant interaction between high-dose methotrexate and high-dose piperacillin-tazobactam causing reversible neurotoxicity and renal failure in an…

2020

Introduction Pharmacokinetic interaction of high-dose methotrexate (MTX) and other concomitantly administered renally secreted medicinal products may lead to insufficient methotrexate serum level decrease and significant MTX toxicity. Case report We report the case of an 18-year-old male patient treated with high-dose MTX for an osteosarcoma and with high-dose piperacillin-tazobactam at the same time. MTX serum levels were severely elevated 24 hours after the MTX infusion and did not decrease in accordance with the specific calcium folinate rescue protocol. The patient experienced renal failure accompanied by neurological symptoms, most consistent with MTX-related renal and CNS toxicity. Ma…

musculoskeletal diseasesMaleAntimetabolites AntineoplasticAdolescentBone Neoplasms030204 cardiovascular system & hematologyPharmacology03 medical and health sciences0302 clinical medicinemedicineHumansPharmacology (medical)Drug InteractionsRenal InsufficiencyPiperacillinOsteosarcomabusiness.industryNeurotoxicitymedicine.diseaseHigh dose methotrexateAnti-Bacterial AgentsMethotrexateOncology030220 oncology & carcinogenesisPiperacillin/tazobactamOsteosarcomaMethotrexateNeurotoxicity SyndromesbusinessPharmacokinetic interactionmedicine.drugJournal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners
researchProduct

Kinetics of Renal Function during Induction in Newly Diagnosed Multiple Myeloma: Results of Two Prospective Studies by the German Myeloma Study Group…

2021

Background: Preservation of kidney function in newly diagnosed (ND) multiple myeloma (MM) helps to prevent excess toxicity. Patients (pts) from two prospective trials were analyzed, provided postinduction (PInd) restaging was performed. Pts received three cycles with bortezomib (btz), cyclophosphamide, and dexamethasone (dex

renal failurekidneyendocrine systemCancer Researchmedicine.medical_specialtyCyclophosphamide030232 urology & nephrologyUrologyRenal functionlcsh:RC254-282NiereninsuffizienzArticleBortezomib03 medical and health sciences0302 clinical medicineMultiple myelomamedicineddc:610Renal insufficiencyLenalidomideDexamethasoneMultiple myelomaLenalidomideKidneybusiness.industryBortezomiblcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensinduction regimenmedicine.disease3. Good healthmedicine.anatomical_structureOncology030220 oncology & carcinogenesisPlasmozytombusinessDDC 610 / Medicine & healthKidney diseasemedicine.drugCancers
researchProduct